期刊文献+

化疗药物在上皮性卵巢癌治疗中的应用及研究进展 被引量:3

原文传递
导出
摘要 目的:综述相关化疗药物在上皮性卵巢癌(EOC)治疗中的应用及不良反应。方法:采用国内、外相关文献进行分析与评价。结果与结论:随着对EOC治疗的不断深入研究,化疗药物及化疗方式也在不断改进,近20年来,经历了由非铂类到铂类化疗,单药化疗到联合化疗,腹腔化疗以及紫杉醇的广泛应用、新型药物的应用等阶段,取得了较好的治疗效果。化疗已成为EOC治疗的重要手段之一,有效的化疗可以及早防止卵巢癌复发,提高治愈率,改善患者生存期。目前紫杉醇联合卡铂被公认为晚期EOC的标准一线化疗方案。
作者 武童 赵纯全
出处 《中国药房》 CAS CSCD 北大核心 2011年第42期4005-4007,共3页 China Pharmacy
  • 相关文献

参考文献17

  • 1Jemal A, Siegel R, Ward E, et al.Cancer statistics, 2007[J]. CA Cancer J Clin,2007 ,57(1) :43.
  • 2Ozols RF, Bundy BN, Greer BE, et al. Phase Ⅲ trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage Ⅲ ovarian cancer: a Gynecologic Oncology Group study[J].J Clin Oncol,2003,21(17) :3 194.
  • 3Armstrong DK.Relapsed ovarian cancer challenges and management strategies for a chronic disease[J]. Oncologist, 2002,7(Suppl 5): 20.
  • 4Tas F, Derin D, Guney N, et al.Chemotherapy with pegylated liposomal doxorubicin and cisplatin in recurrent platinum-sensitive epithelial ovarian cancer[J]. Int J Clin Oncol,2008,13(4) :330.
  • 5Desoize B, Madoulet C.Particular aspects of platinum compounds used at present in cancer treatment[J].Crit Rev Oncol Hematol, 2002,42 (3) : 317.
  • 6颜冬梅,李文钧,彭小英.铂类抗肿瘤药物的研究近况[J].中国药房,2005,16(13):1022-1025. 被引量:11
  • 7Markman M, Kennedy A, Webster K, et al.Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum[J]. J Clin Oncol, 2001,19 (7) : 1 901.
  • 8Rose PG, Blessing JA, Ball HG, et al.A phase Ⅱ study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study[J].Gynecol Oncol, 2003,88 (2): 130.
  • 9Gore M, Huinink W, Carmichael J, et al.Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovarian cancer[J].J Clin Oncol, 2001,19 ( 7 ) : 1 893.
  • 10Pignata S, Scambia G, Savarese A, et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase Ⅲ trial [J].Oncology, 2009,76 ( 1 ) : 49.

二级参考文献22

  • 1管忠震,徐瑞华.奈达铂临床研究进展[J].中国肿瘤临床,2004,31(13):774-780. 被引量:176
  • 2李文钧,郑永兴.石墨炉原子吸收法测定体内顺铂[J].药物分析杂志,1989,9(2):82-85. 被引量:10
  • 3Grothey A, Goldberg RM.A review of oxaliplatin and its clinical use in colorectal cancer[J] .Expert Opin Pharmacother, 2004,5(10) : 2 159.
  • 4Miyagi Y, Kawanishi K, Miyagi Y, et al .Cytocidal effect and DNA damage of nedaplatin:a mathematical model and analysis of experimental data[J] .Cancer Chem Pharmacol, 2001,47(3) : 229.
  • 5McKeage MJ .Lobaplatin: a new antitumour platinum drug[J]. Expert Opin Investig Drugs, 2001,10(1) : 119.
  • 6Kim DK, Kim HT, Cho YB, et al .Antitumor activity of cis-malonato[ (4R, 5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane] platinum(Ⅱ),a new platinum analogue,as an anticancer agent[J]. Cancer Chem Pharmacol, 1995,35(5) : 441.
  • 7Min Y J, Bang SJ, Shin JW, et al . Combination chemotherapy with 5 - fluorouracil and heptaplatin as first- line treatment in patients with advanced gastric cancer[J] .J Korean Med Sci, 2004,19(3) :3 693.
  • 8Kelland LR. An update on satraplatin: the first orally available platinum anticancer drug[J] .Expert Opin Investig Drugs, 2000,9(6):1 373.
  • 9Kurata T, Tamura T, Sasaki Y, et al .Pharmacokinetic and pharmacodynamic analysis of bis - acetato - ammine - dichloro - cyclohexylamine - platinum( Ⅳ )(JM216) administered once a day for five consecutive days: a phase I study[J] .Jpn J Clin Oncol ,2000,30(9) :377.
  • 10Latif T,Wood L,Connell C,et al .Phase Ⅱ study of oral bis(aceto) ammine dichloro(cyclohexamine) platinum( IV ) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer(HRPC) [J] . Invest New Drugs, 2005,23(1) : 79.

共引文献10

同被引文献24

  • 1刘晶煜.艾迪与鸦胆子油乳治疗肿瘤成本-效果分析[J].中国药房,2007,18(14):1049-1050. 被引量:5
  • 2中华人民共和国医政司.常见恶性肿瘤诊治范[M].北京:中国协和医科大学出版社,1999:773-778.
  • 3李晓琴,姬发祥,林明哲,等.多西他赛联合奥沙利铂治疗晚期胃癌的临床观察[J].中国新药杂志,2012,19(12):1498-2501.
  • 4Roett MA, Evans P. Ovarian cancer: an overview[J]. Am Fam Physician, 2009,80 (6) : 609.
  • 5Liu J, Matulonis UA. New advances in ovarian cancer[J]. Oncology ( Williston Park), 201 0, 24 (8) : 721.
  • 6Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response crite- ria in solid tumors[J]. J Nucl Med, 2009, 50 (Suppl 1) : 122S.
  • 7National Institutes of Health, National Cancer Institute NCI. Common Terminology Criteria for Adverse Events ( CT- CAE ) : Version 4.0[EB/OL]. (2010-06-14) [2015-02-01]. http ://wenku.baidu.corn/link?url=VCRQRrzMkmYRyNcc- gy4S liNTdlTQ mnibFHhk6iGSLF3xbC 78Aueddih4NzW- zB_264Bdb8hMVNHLj Q6vEoGNY6-T4AC 3L-MUjZ- wkGk0vkCy.
  • 8宋坤,孔北华.卵巢癌靶向治疗的现状与展望[J].中国实用妇科与产科杂志,2008,24(9):709-711. 被引量:3
  • 9顾军,韩香,张磊.多西他赛用于卵巢癌治疗临床研究进展[J].天津药学,2008,20(5):68-70. 被引量:7
  • 10王淳,李士怡,王晓波,董秀,刘春英.消癌平注射液通过PI3K/Akt信号通路调节卵巢癌细胞增殖研究[J].中国中医药信息杂志,2010,17(S1):28-30. 被引量:19

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部